Document is current
Any future updates will be listed below
-
Authors
Lintel, Hendrik
Abbas, Darren B.
Lavin, Christopher V.
Griffin, Michelle
Guo, Jason L.
Guardino, Nicholas
Churukian, Andrew
Gurtner, Geoffrey C.
Momeni, Arash
Longaker, Michael T.
Wan, Derrick C. http://orcid.org/0000-0003-4666-1683
-
Funding
Funding for this research was provided by:
National Institute of Dental and Craniofacial Research (R01DE027346, U24DE029463)
- License Information
-
More Information
Article History
Received: 20 April 2022
Accepted: 11 June 2022
First Online: 17 June 2022
Declarations
:
: All animal experiments were conducted in accordance with the animal welfare guidelines and approval of the Administrative Panel on Laboratory Animal Care (APLAC) at Stanford University.
: Not applicable.
: MTL and GCG own equity in TauTona group which supplied the DFO patches. GCG owns a patent for transdermal delivery of HIF1α modulators. GCG, MTL and DCW hold a patent for the application of DFO for the treatment of irradiated tissue. All other authors have no conflict of interest.
